https://www.zacks.com/stock/news/2261525/will-united-therapeutics-uthr-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2261525
Apr 24, 2024 - United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:-2524990115245587414
0
https://www.zacks.com/stock/news/2247989/why-is-jazz-jazz-up-1-3-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2247989
Mar 29, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
zc:1769241270691690798
0
https://www.zacks.com/stock/news/2247384/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2247384
Mar 28, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zc:-7213056305887733041
0
https://www.zacks.com/stock/news/2230417/united-therapeutics-uthr-q4-earnings-sales-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2230417
Feb 22, 2024 - United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.
zc:2734424688614012520
0
https://www.zacks.com/stock/news/2230183/why-united-therapeutics-uthr-is-a-top-growth-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2230183
Feb 22, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
zc:578762675940540370
0
https://www.zacks.com/stock/news/2227830/unveiling-united-therapeutics-uthr-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227830
Feb 19, 2024 - Get a deeper insight into the potential performance of United Therapeutics (UTHR) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
zc:-1466773526700379282
0
https://www.zacks.com/stock/news/2227400/henry-schein-hsic-set-to-post-q4-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2227400
Feb 16, 2024 - Henry Schein's (HSIC) fourth-quarter 2023 results are likely to reflect the resiliency of the dental and medical markets amid macroeconomic challenges.
zc:-5587068660419963111
0
https://www.zacks.com/stock/news/2226923/relay-therapeutics-inc-rlay-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2226923
Feb 15, 2024 - Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:6040348897376728593
0
https://www.zacks.com/stock/news/2222795/will-united-therapeutics-uthr-beat-estimates-again-in-its-next-earnings-report?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2222795
Feb 07, 2024 - United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:-8726963146848234140
0
https://www.zacks.com/stock/news/2196169/why-united-therapeutics-uthr-is-a-top-growth-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2196169
Dec 11, 2023 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zc:-8115770279650577015
0